Please assess the completion status of the following clinical trial:

Trial Title: Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of MCI defined as abnormal cognition on objective testing in the absence of dementia or significant functional loss.~* Absence of systemic or other neurological disease that may contribute to cognitive impairment or prevent follow-up over two years.~* Able to give written informed consent.~* Age \>/= 60 years of age~* \>/= 7 years of education~Exclusion Criteria:~* Mini mental state examination (MMSE) score \< 24 at baseline~* Clinical dementia rating (CDR) score \> 0.5 at baseline~* Patients who receive regular medication of drugs which may adversely impact cognition (e.g. tricyclic antidepressants, antipsychotics and/or large doses of hypnotics or anxiolytics)~* Existing or history of cancer~* History of severe head trauma, brain surgery or intracranial hematoma with permanent brain lesion~* Lifetime history of major affective disorder, schizophrenia, or schizo-affective disorder~* Contraindications to MRI (Magnetic resonance imaging)~* Relevant history, physical or imaging findings of neurological disease other than MCI and mild depression~* History of severe anaphylactic reaction or high risk of allergic reaction to drugs~* Patient has received another investigational drug in the preceding 14 days

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).